Patents Assigned to Mochida Pharmaceuticals Co., Ltd.
  • Patent number: 9345681
    Abstract: The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: May 24, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Ishida, Hiroyuki Kawano
  • Publication number: 20160115542
    Abstract: Provided is FGF21 that is a metabolism-related biomarker reflecting the activation of Nrf2 in vivo. Also provided are a method for monitoring a response of a subject to which an Nrf2 activator is administered, said method comprising a step for measuring the FGF21 level, at a point during or after the administration of the Nrf2 activator, in a biosample that is derived from the subject, wherein an increase in the FGF21 level indicates a positive response to the administration of the Nrf2 activator, etc. According to the present invention, a metabolism-related biomarker that reflects the activation of Nrf2 in vivo is provided.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 28, 2016
    Applicants: Mochida Pharmaceutical Co., Ltd., Tohoku University
    Inventors: Masayuki Yamamoto, Akira Uruno, Yuki Furusawa
  • Publication number: 20160089355
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Application
    Filed: December 9, 2015
    Publication date: March 31, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
  • Patent number: 9297802
    Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the urine sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 29, 2016
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Patent number: 9291631
    Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 22, 2016
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20160067309
    Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 10, 2016
    Applicants: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa IWASAKI, Atsushi SUKEGAWA, Akio MINAMI, Nobuo OHZAWA
  • Publication number: 20160045469
    Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO, Yuichi ISHIKAWA, Shinichi OIKAWA, Jun SASAKI, Hitoshi HISHIDA, Hiroshige ITAKURA, Toru KITA, Akira KITABATAKE, Noriaki NAKAYA, Toshiie SAKATA, Kazuyuki SHIMADA, Kunio SHIRATO
  • Publication number: 20160030378
    Abstract: The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HARADA, Hideo KANEHIRO, Kiyoshi MIZUGUCHI
  • Patent number: 9233093
    Abstract: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: January 12, 2016
    Assignee: MOCHIDA PHARMACEUTICALS CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Publication number: 20150368269
    Abstract: The present invention provides a compound of Formula (I) where A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: December 16, 2013
    Publication date: December 24, 2015
    Applicants: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Cameron James Smith, Edward Sherer, Louis-Charles Campeau, James Balkovec, William John Greenlee, Derun Li, Liangqin Guo, Tin-Yau Chan, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, John Qiang Tan, Tomokazu Hirabayashi, Mika Sekioka
  • Patent number: 9216201
    Abstract: The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 22, 2015
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Fumiyoshi Kasahara, Chihiro Miyajima, Nobuo Ohzawa, Mariko Imai
  • Patent number: 9198892
    Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: December 1, 2015
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura, Toru Kita, Akira Kitabatake, Noriaki Nakaya, Toshiie Sakata, Kazuyuki Shimada, Kunio Shirato
  • Publication number: 20150329562
    Abstract: The present invention provides a compound of Formula (I) wherein R1, R2, R3 and R4 are independently H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl, and when R2, R3, and R4 are H, R is C1-6 alkyl; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 19, 2015
    Applicants: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Cameron James Smith, John Qiang Tan, Ting Zhang, James Balkovec, William John Greenlee, Liangqin Guo, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, Tomokazu Hirabayashi, Mika Sekioka
  • Publication number: 20150322056
    Abstract: The present invention provides a compound of Formula (I) wherein R1 is H or C1-6 alkyl, R2, is H or C1-6 alkyl or CH2OH, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or —CH2OH, and when R2, R3, and R4 are H, then R1 is C1-6 alkyl; A is 1) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and O, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with —CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or O, which is unsubstituted or substitut
    Type: Application
    Filed: December 16, 2013
    Publication date: November 12, 2015
    Applicants: Mochida Pharmaceutical Co., Ltd., Merck Sharp & Dohme Corp.
    Inventors: Cameron James SMITH, John Qiang TAN, Ting ZHANG, James BALKOVEC, William John GREENLEE, Liangqin GUO, Yi-Heng CHEN, Yili CHEN, Jiayi XU, Samuel CHACKALAMANNIL, Tomokazu HIRABAYASHI, Hiroshi NAGASUE, Kouki OGAWA
  • Publication number: 20150283074
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Application
    Filed: June 22, 2015
    Publication date: October 8, 2015
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato FUJII, Motoo Yamagata
  • Publication number: 20150266839
    Abstract: [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or the like. [Means of Solving the Problem] A compound of Formula (III): (where f is 0 to 2; g is 1 to 4; j is 0 to 3; k is 0 to 2; n is 0 to 2; p is 0 to 4; his 0 to 3; q1 id 0 to 3; q2 is 0 or 1; r1 is 0 to 2 (with the proviso that q1+q2+r1 is 0 to 5); J1a is —CR11a—, N; J2 is —CR12aR12b—, —CR12c—; T is —CH2—, O, —S(O)i— (i is an integer of 0 to 2) or —NR7—; X is O, S, or —NR7—; ring A?? is a benzene ring, a pyridine ring; ring B? is a benzene ring, a pyridine ring, a pyrimidine ring; and R1 to R14 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    Type: Application
    Filed: June 3, 2015
    Publication date: September 24, 2015
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro OKANO, Munetaka OHKOUCHI, Muneyoshi MAKABE
  • Publication number: 20150258054
    Abstract: Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: October 12, 2012
    Publication date: September 17, 2015
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD
    Inventors: Kiyoshi Mizuguchi, Tsuyoshi Harada, Atsushi Osada, Hiroyuki Kawano, Masayuki Ichioka
  • Publication number: 20150250754
    Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.
    Type: Application
    Filed: September 19, 2013
    Publication date: September 10, 2015
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko Ohta, Shinichi Oikawa, Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Publication number: 20150247869
    Abstract: Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventors: Ayumi SATO, Tsuyoshi HARADA, Takashi YANO, Yoko WAKABAYASHI
  • Publication number: 20150239982
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Application
    Filed: February 25, 2015
    Publication date: August 27, 2015
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA